NEW YORK, NY--(Marketwired - November 11, 2015) - Cell Source, Inc. (CLCS) a biotechnology company focused on developing cell therapy treatments based on immunotherapy and regenerative medicine, ...
No controlled studies of megadose intravenous (IV) corticosteroids (1 gr/day methylprednisolone) for NAION have been performed. Some clinicians tend to recommend this approach in severe progressive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results